Our team recently attended two leading forums focused on the future of MASH research and treatment: the 2026 Paris MASH Meeting and the 10th MASH Drug Development Summit in Boston. Together, the conferences brought perspectives from clinical pract...
Drawing on the experience and perspectives of Prof. Dr. Manuel Castro Cabezas, Scientific Officer at P95 Julius Clinical, and Prof. Dr. Diederick (Rick) E. Grobbee, Chief Scientific Officer at P95 Julius Clinical, this article explores how sponsor...
MASH CRO Expertise for Complex Clinical Trials As MASH clinical development continues to evolve, sponsors face increasing challenges in patient identification, complex eligibility criteria, high screening failure rates, and competition for experi...
Comparing FIB-4 and MAF-5 for Advanced Fibrosis Screening in Primary Care Complete the form to access the poster and explore the preliminary GRIPonMASH findings.[gravityform id="19" title="false"]As the prevalence of MASLD and MASH contin...
The GRIPonMASH consortium has reached a significant milestone in screening individuals at risk of metabolic dysfunction-associated steatotic liver disease (MASLD). Julius Clinical is proud to contribute to this achievement.The GRIPonMASH conso...
Metabolic dysfunction-associated steatohepatitis, or MASH, is gaining attention across the medical community, but for many patients it remains a largely silent disease. Closely linked with obesity, type 2 diabetes and other cardiometabolic risk fa...
15 May 2025, The NetherlandsJulius Clinical’s Scientific Officer, practising internist, and founding member of the Dutch Thyroid Network (Schildkliernetwerk - Home), Dr Manuel Castro Cabezas, was delighted to sit down with Dr Marco Medici, a...
A paper published in Clinical Rheumatology from the research group of our Scientific Officer Manuel Castro Cabezas and Chief Scientific Officer Rick Grobbee indicates that patients with rheumatoid arthritis with high liver fibrosis scores are like...
What are the clinical consequences of the new MASLD nomenclature, and how does it change our understanding of steatotic liver disease? The introduction of the new steatotic liver disease (SLD) nomenclature marks a significant shift in the field, ...
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThe estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...
"*" indicates required fields
"*" indicates required fields
